ArticleTherapeutic delivery2025
Curcumin-loaded PEG-functionalized carbon nanotubes: a novel strategy for Alzheimer's management.
Article in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Curcumin nanoformulations for modulating neuroinflammation and oxidative stress in Alzheimer's disease: blood-brain barrier transport, formulation strategies and therapeutic applications.Inflammopharmacology · 2026Review
- Smart Biosensing Nanomaterials for Alzheimer's Disease: Advances in Design and Drug Delivery Strategies to Overcome the Blood-Brain Barrier.Biosensors · 2026Review
- Curcumin-based biocompatible nanocarriers: a contemporary perspective in functional foods and biomedical applications.Discover nano · 2025Review
- Plants, Pills, and the Brain: Exploring Phytochemicals and Neurological Medicines.International journal of plant, animal and environmental sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsCurcumin (CUR) exhibits strong therapeutic potential for Alzheimer's disease due to its antioxidant, neuroprotective, anti-inflammatory, and anti-amyloid effects. However, its clinical application is limited by poor brain bioavailability. This study aimed to enhance CUR delivery to the brain via nasal administration using a novel formulation of polyethylene glycol (PEG)-functionalized carboxylated (COOH) Multi-Walled Carbon Nanotubes (MWCNT). MATERIALS AND
methodsCUR-loaded MWCNT-COOH-PEG was developed and optimized using a 3
resultsThe formulation achieved an entrapment efficiency of 91.4 ± 0.8%, a zeta potential of -31.1 ± 1.05 mV, and a particle size of 310 ± 7.92 nm. In vitro release was 95.42 ± 0.0004% at pH 5.5 and 89.98 ± 0.0039% at pH 7.4. CUR at 18.75 µg/mL inhibited apoptosis in PC12 cells after 24 h. Higher brain CUR concentrations were observed 4 h post-administration.
conclusionCUR-loaded MWCNT-COOH-PEG effectively enhances brain bioavailability of CUR, demonstrating significant neuroprotective effects, and offers a promising approach for Alzheimer's therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.